Financhill
Back

Galecto Quote, Financials, Valuation and Earnings

Galecto Price Quote

$4.94
+0.22 (+6.01%)
(Updated: December 21, 2024 at 5:28 AM ET)

Galecto Key Stats

Sell
21
Galecto (GLTO) is a Sell

Day range:
$4.66 - $4.86
52-week range:
$4.40 - $23.50
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
0.00
P/B ratio:
0.3%

Volume:
15.2K
Avg. volume:
17.6K
1-year change:
-69.04%
Market cap:
$6.2M
Revenue:
$0
EPS:
$-19.2

How Much Does Galecto Make?

Data Unavailable

Is Galecto Growing As A Company?

Data Unavailable

Galecto Stock Price Performance

  • Did Galecto Stock Go Up Last Month?
    Galecto share price went down by -18.76% last month
  • Did GLTO's Share Price Rise Over The Last Year?
    GLTO share price fell by -69.04% over the past 1 year

What Is Galecto 52-Week High & Low?

  • What Is Galecto’s 52-Week High Share Price?
    Galecto has traded as high as $23.50 over the past 52 weeks
  • What Is Galecto’s 52-Week Low Share Price?
    Galecto has traded as low as $4.40 over the past 52 weeks

Galecto Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Galecto?

Data Unavailable

Is Galecto Cash Flow Positive?

Data Unavailable

Galecto Return On Invested Capital

Data Unavailable

Galecto Earnings Date & Stock Price

  • What Is Galecto's Stock Price Today?
    A single share of GLTO can be purchased today for 4.72
  • What Is Galecto’s Stock Symbol?
    Galecto trades on the nasdaq under the ticker symbol: GLTO
  • When Is Galecto’s Next Earnings Date?
    The next quarterly earnings date for Galecto is scheduled on April 29, 2025
  • When Is GLTO's next ex-dividend date?
    Galecto's next ex-dividend date is December 22, 2024
  • How To Buy Galecto Stock?
    You can buy Galecto shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.

Galecto Competitors

  • Who Are Galecto's Competitors?
    Below is a list of companies who compete with Galecto or are related in some way:
    • Ascendis Pharma AS (ASND)
    • Evaxion Biotech AS (EVAX)
    • Genmab AS (GMAB)
    • IO Biotech Inc (IOBT)
    • Novo Nordisk AS (NVO)

Galecto Dividend Yield

Data Unavailable

Galecto Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 8.38%
Revenue: 0% 0%

Analyst Recommendations

Buy Recommendations: 0
Hold Recommendations: 0
Sell Recommendations: 0
Price Target: 0.00
Downside from Last Price: -100%

Major Shareholders

Data Unavailable